Open AccessNeuroleptic Malignant Syndrome Associated with Haloperidol
Author(s) -
Fajlul Kabir Bhuiyan
Publication year - 2020
Publication title -
taj
Language(s) - English
Resource type - Journals
eISSN - 2408-8854
pISSN - 1019-8555
DOI - 10.3329/taj.v32i2.44901
Subject(s) - haloperidol , bromocriptine , lorazepam , neuroleptic malignant syndrome , discontinuation , medicine , anesthesia , psychology , psychiatry , dopamine , prolactin , hormone
A 42-year-old adult schizophrenic patient developed high fever (106 degree Fahrenheit), mental state changes and muscle rigidity after treatment with parenteral haloperidol. Neuroleptic malignant syndrome (NMS) associated with haloperidol was suspected. Other differentials were excluded. Haloperidol was discontinued and prompt treatment with bromocriptine and lorazepam was started resulting in a good recovery. Because of the temporal relationship between the patient's improvement with the discontinuation of haloperidol and treatment with lorazepam and bromocriptine, the diagnosis was believed to be haloperidol-induced NMS.
TAJ 2019; 32(2): 62-63